Do you want to read an article? Please log in or register.
Perioperative Apalutamide in High-Risk Localized Prostate Cancer
Genitourinary Cancer
Related content
CHICAGO 2026
Genitourinary Cancer
LBA1: PROTEUS: The final analysis supports perioperative apalutamide plus ADT in patients with high-risk localized or locally advanced prostate cancer
Genitourinary Cancer
Predicting the indication for adjuvant radiation therapy according to EAU guidelines among patients with high-risk prostate cancer: a novel multivariable model
Prostate Cancer Prostatic Dis
Siech C, von Kriegstein H, Wenzel M, Cano Garcia C, Le QC, Tennstedt P, Preisser F, Maurer T, Kriegmair M, Chun FKH, Graefen M, Tilki D, Mandel P
doi: 10.1038/s41391-025-01018-y
ESMO 2025
Genitourinary Cancer
EMBARK: Enzalutamide plus leuprolide significantly improves OS in high-risk biochemically recurrent prostate cancer
Genitourinary Cancer
Enzalutamide with or without leuprolide in patients with high-risk biochemically recurrent prostate cancer: EMBARK post hoc analysis by age
Eur J Cancer
Shore ND, De Giorgi U, Kalac M, Tang Y, Croitoru R, Rosales M, Huynh MJ, de Jong IJ, Evans CP, Carcano FM, Freedland SJ
doi: 10.1016/j.ejca.2025.116110
Genitourinary Cancer
Multimodal Artificial Intelligence Prediction of Abiraterone Efficacy in Two STAMPEDE Phase 3 Trials of Non-Metastatic Very High-Risk Prostate Cancer
Ann Oncol
Parker CTA, Huang HC, Grist E, Mendes L, Yamashita R, Croucher D, Sachdeva A, Murphy L, Liu VYT, Vidal SS, Todorovic T, Lall S, Goncalves M, Thakali S, Wingate A, Zakka L, Wetterskog D, Nowakowska K, Amos CL, STAMPEDE Collaborators, Berney DM, Tran PT, Spratt DE, Sydes MR, Brown LC, Zhao SG, Nguyen P, Clarke NW, Sweeney CJ, Stewart EL, Parmar MKB, Esteva A, James ND, Attard G
doi: 10.1016/j.annonc.2026.05.708
Genitourinary Cancer
Disease progression patterns and association of prostate-specific antigen level with risk of progression in nonmetastatic castration-resistant prostate cancer
Prostate Cancer Prostatic Dis
Morgans AK, Wallis CJD, Halabi S, Armstrong AJ, Adorjan P, Ghadessi M, Verholen F, Grimm MO
doi: 10.1038/s41391-026-01076-w
Genitourinary Cancer
Effect of [(68)Ga]Ga-PSMA-11 PET-CT in the diagnosis of prostate cancer in men with equivocal or clinically high-risk non-suspicious findings on multiparametric MRI (PRIMARY2): a multicentre, non-inferiority, phase 3, randomised controlled trial
Lancet Oncol
Buteau JP, Moon D, Fahey MT, Roberts MJ, Ayati N, Papa N, Murphy DG, Kasivisvanathan V, Dhillon HM, Du YT, Dundee P, Foudoulis J, Hennes D, Hutton AC, Idiare J, Jack G, Kamath S, Lee SN, Lee SF, Lee ST, Leslie S, Levy SM, Link E, Mitchell C, Morigi JJ, Nguyen A, Olphert J, Patel MI, Pattison DA, Pearce A, Perera M, Thanigasalam R, Thomson A, Yaxley J, Thompson J, Hofman MS, Emmett L, PRIMARY2 Trial Investigators
doi: 10.1016/S1470-2045(26)00120-8
COMMENTED
Genitourinary Cancer
Treatment of High-Risk Biochemically Recurrent Prostate Cancer With Enzalutamide in Combination With Leuprolide: Secondary Endpoints From the EMBARK Trial
★ 1
Recommended and commented by
Prof. Dr Richard Cathomas, Faculty Member
J Urol
Shore ND, Gleave M, De Giorgi U, Rannikko A, Pieczonka CM, Sridharan S, Brasso K, Woo HH, Gómez Caamaño A, Saranchuk JW, Nordquist LT, Ferreira U, Tang Y, Rosbrook B, Haas GP, Rosales M, Zohren F, Tarazi J, Freedland SJ
doi: 10.1097/JU.0000000000004890
Genitourinary Cancer
Fracture-related hospitalisations in newly diagnosed high-risk localised or metastatic hormone-sensitive prostate cancer: secondary analysis of the STAMPEDE phase 3 trials of docetaxel and zoledronic acid using healthcare systems data
Ann Oncol
Jones C, Dutey-Magni P, Murphy LR, Murray ML, Brown JE, McCloskey E, Brown M, Amos CL, Gilbert DC, Jones RJ, Cross W, Matheson D, Millman R, Parmar MKB, Attard G, Sydes MR, Brown LC, James ND, Clarke NW, Sachdeva A, STAMPEDE Trial Investigators
doi: 10.1016/j.annonc.2025.07.005